OBJECTIVES: Viral load (VL) measurement is critical for monitoring the effectiveness of highly active antiretroviral therapy (HAART). HAART aims to maintain plasma HIV RNA at undetectable levels. A VL <50 copies/ml was previously considered undetectable. After introducing more sensitive assays many patients with VL <50 copies/ml were found to have very low-level viraemia (VLLV), defined as a detectable VL <40 copies/ml. This study aimed to determine the significance of VLLV. METHODS: This retrospective case-control study included 69 individuals on HAART with VLLV. Immunological and virological outcomes over 36 months were compared to those of 70 well-matched controls with persistently undetectable VL. RESULTS: We detected no significant association between VLLV and the development of virological failure or inferior immunological outcomes. However, individuals with VLLV were significantly less likely to achieve subsequent sustained virological suppression (VL <50 copies/ml, p<0.001), including completely undetectable suppression (undetectable VL <40 copies/ml, p=0.002). CONCLUSIONS: The significance of VLLV has been uncertain. Our results clearly suggest that VLLV is predictive of future suboptimal virological control, particularly a reduced likelihood of achieving virological suppression. Further work should confirm our findings and evaluate strategies for managing VLLV in HAART-treated patients.
OBJECTIVES: Viral load (VL) measurement is critical for monitoring the effectiveness of highly active antiretroviral therapy (HAART). HAART aims to maintain plasma HIV RNA at undetectable levels. A VL <50 copies/ml was previously considered undetectable. After introducing more sensitive assays many patients with VL <50 copies/ml were found to have very low-level viraemia (VLLV), defined as a detectable VL <40 copies/ml. This study aimed to determine the significance of VLLV. METHODS: This retrospective case-control study included 69 individuals on HAART with VLLV. Immunological and virological outcomes over 36 months were compared to those of 70 well-matched controls with persistently undetectable VL. RESULTS: We detected no significant association between VLLV and the development of virological failure or inferior immunological outcomes. However, individuals with VLLV were significantly less likely to achieve subsequent sustained virological suppression (VL <50 copies/ml, p<0.001), including completely undetectable suppression (undetectable VL <40 copies/ml, p=0.002). CONCLUSIONS: The significance of VLLV has been uncertain. Our results clearly suggest that VLLV is predictive of future suboptimal virological control, particularly a reduced likelihood of achieving virological suppression. Further work should confirm our findings and evaluate strategies for managing VLLV in HAART-treated patients.
Authors: J Saison; T Ferry; J Demaret; D Maucort Boulch; F Venet; T Perpoint; F Ader; V Icard; C Chidiac; G Monneret Journal: Clin Exp Immunol Date: 2014-06 Impact factor: 4.330
Authors: Silvia Baroncelli; Maria Franca Pirillo; Clementina Maria Galluzzo; Anna Degli Antoni; Nicoletta Ladisa; Daniela Francisci; Gabriella d'Ettorre; Daniela Segala; Angela Vivarelli; Federica Sozio; Oscar Cirioni; Liliana Elena Weimer; Vincenzo Fragola; Giustino Parruti; Marco Floridia Journal: AIDS Res Hum Retroviruses Date: 2015-01 Impact factor: 2.205
Authors: Patrick Ryscavage; Sean Kelly; Jonathan Z Li; P Richard Harrigan; Babafemi Taiwo Journal: Antimicrob Agents Chemother Date: 2014-04-14 Impact factor: 5.191
Authors: Gisela Leierer; Katharina Grabmeier-Pfistershammer; Andrea Steuer; Mario Sarcletti; Maria Geit; Bernhard Haas; Ninon Taylor; Manfred Kanatschnig; Michaela Rappold; Bruno Ledergerber; Robert Zangerle Journal: Open Forum Infect Dis Date: 2016-06-15 Impact factor: 3.835